BOT (ASX) Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3

Originally posted by Southoz: ↑

I put this little conundrum (why placebo differences between US versus Aussie) into my brain last thing last night … and woke up this morning with the obvious answer.

Compliance.

Imagine you are a teenage boy (girl) with a hot date Saturday night. Confidence is going to be everything and bad acne is hardly helpful for that. The treatment you are on (the placebo) is doing bugger all and so despite strict instructions to the contrary you will start experimenting with alternative approaches.

Its an emergency after all.

But why would compliance be lower in the US compared with Australia? Boys / girls are equally randy the world over.

Therapeutic alliance.

In the US the sites are predominately contract research centres. Conducting trials is their business. The Australia sites are predominately dermatology clinics – their business is treating people.

One is motivated by purely money the other business is motivated by helping people (and making money).

Teenagers are a particularly tricky clientele for clinical trials - because their altruism levels are low. The world revolves around them … as opposed to older people who take part in trials to feel useful and contribute something back to society.

So you are at great risk with younger people for poor compliance. They don’t care. Which is the opposite for older people who sometimes care too much … and worry excessively about doing the wrong thing and ruining your good work.

That existing relationship with a treating health care professional is what gets you good recruitment and good compliance in a clinical trial. Subtract that – as what occurs in these US research units and you lose that element of not wanting to let your doctor / health professional (who has cared about you) down.

So that’s the theory – how would you confirm it? It’s difficult because you do not have a objective measure of compliance.

But I would expect higher US attrition (drop-outs). And baseline participants differences between the US / Australia – with the US lower SES.

Many trials include a measure of allocation blinding – can participants correctly guess what treatment they were receiving. I would expect this to be above chance for the placebo group – hence increasing the risk the people wandering off protocol.

People have pointed to parallels with RAP. Good Aussie results poor US results. It is similar but not quite the same.

In the RAP Ausssie trials the research team was the clinical team. In the US through a CRO in a tier one hospital there is a strict separation between the research team and the clinical team. Naturally this produces poorer quality data (the clinical team care very little for getting good data – they care about getting good patient outcomes) … which the US adjudicators then find difficult to make consistent diagnoses on.

Here you don’t have that problem … but it is the same in that the context of the implementation is having a big impact on outcomes.

This might all seem insightful. But in fact its only learned through error.

I have recently been part of a US research group that has just made this same mistake and lost several million dollars. In upscaling we moved to a good research group. But we lost the therapeutic alliance element that we had had with participants in our earlier trials. We sort of took it for granted – not fully appreciating how vital it was for compliance. So compliance dropped through the floor and on an ITT basis the results are terrible.

So take this with a big pinch of salt … but there is probably a better story here. Albeit you would like a confirmation of something somewhere of what I am saying. But none of us can pick up the phone and chew the fat with the PIs here for a hour. So big uncertainty … not for the faint hearted … but perhaps worth a punt that the mob is going to get this wrong.

Expand

I think that's a very good angle on the potential cause of the discrepancy. It's obviously just a theory but definitely something that will have to be investigated when structuring P3.

Luckily we have BTX 1204 result due shortly which will also provide more statistical insight into trial structuring.

BOT still has the same potential upside as it did a few days ago. We just need some clarification from management as to why there is the discrepancy.

No.	Vol.	Price($)
6	229793	36.0¢

No.

Vol.

Price($)

229793

36.0¢

Price($)	Vol.	No.
36.5¢	227289	5

Price($)

Vol.

No.

36.5¢

227289

No.	Vol.	Price($)
6	229793	0.360
13	955661	0.355
10	807826	0.350
7	360693	0.345
13	1746473	0.340

No.

Vol.

Price($)

229793

0.360

955661

0.355

807826

0.350

360693

0.345

1746473

0.340

Price($)	Vol.	No.
0.365	227296	5
0.370	37397	4
0.375	475054	3
0.380	460554	18
0.385	191153	6

Price($)

Vol.

No.

0.365

227296

0.370

37397

0.375

475054

0.380

460554

0.385

191153

(20min delay)
Last 36.5¢		Change -0.015(3.95%)		Mkt cap ! $687.8M

Open	High	Low	Value	Volume
37.5¢	37.5¢	35.0¢	$1.972M	5.430M

Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-280

Asara Resources sells off Burkina Faso assets to pivot into Guinea – for US$13M less than last time it tried

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Great Boulder lines up two new WA gold targets, extends Side Well mineralisation to 18km

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Bitcoin investors need to know the risks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-280

Top Stories

Asara Resources sells off Burkina Faso assets to pivot into Guinea – for US$13M less than last time it tried

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Great Boulder lines up two new WA gold targets, extends Side Well mineralisation to 18km

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Bitcoin investors need to know the risks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News